

1 **Economic effects of a country-level tobacco endgame strategy: a**  
2 **modelling study**

3

4 **Authors**

5 Driss Ait Ouakrim, PhD

6 Tim Wilson, PhD

7 Samantha Howe, MPH

8 Philip Clarke, PhD

9 Coral Gartner, PhD

10 Nick Wilson, MBChB

11 Tony Blakely, PhD

12 **Abstract**

13

14 **Background**

15 Aotearoa-New Zealand (A/NZ) is the first country to pass a comprehensive commercial  
16 tobacco endgame strategy into law. Key components include the denicotinisation of smoked  
17 tobacco products and a major reduction in tobacco retail outlets. Understanding the  
18 potential long-term economic impacts of these measures is important for government  
19 planning.

20

21 **Methods**

22 A tobacco policy simulation model that evaluated the health impacts of the A/NZ Smokefree  
23 Action Plan was extended to evaluate the economic effect of the new measures from both  
24 Government and citizen perspectives. Estimates were discounted at 3% per annum and  
25 presented in 2021 purchasing power parities US\$.

26

27 **Findings**

28 The modelled endgame policy package generates considerable growth in income for the  
29 A/NZ population with a total cumulative gain by 2050 amounting to US\$31 billion. From a  
30 government perspective, the policy results in foregone tobacco excise tax revenue with a  
31 negative net financial position estimated at US\$11.5 billion by 2050. In a sensitivity analysis  
32 considering future changes to labour workforce, the government's cumulative net position  
33 remained negative by 2050, but only by US\$1.9 billion.

34

35 **Interpretation**

36 Our modelling suggests the Smokefree Aotearoa 2025 Action Plan is likely to produce  
37 substantial economic benefits for the A/NZ population, and modest impacts on government  
38 revenue and expenditure related to the reduction in tobacco tax and increases in aged  
39 pensions due to increased life expectancy. Such costs can be anticipated and planned for  
40 and might be largely offset by future increases in labour force and the proportion of 65+  
41 year olds working in the formal economy.

42

43 **Funding**

44 This study was funded by a grant from the Australian National Health and Medical Research  
45 Council (GNT1198301)

## 46 **Research in Context**

### 47 **Evidence before this study**

48 Multiple countries have set targets to achieve a commercial tobacco endgame. Most  
49 simulation modelling studies have evaluated 'traditional' tobacco control interventions (e.g.,  
50 tobacco excise tax increases, indoor smoking bans, smoking cessation health services). Very  
51 few have modelled the economic effects of endgame strategies. We searched PubMed with  
52 no language restrictions for articles published from 1 January 2000 to 8 February 2023 using  
53 the following search terms: (smoking[TW] OR tobacco[TW]) AND (endgame[TW] OR  
54 eliminat\*[TW] OR "phasing out"[TW] OR "phase out"[TW] OR aboli\*[TW] OR prohibit\*[TW]  
55 OR ban[TW] OR "smoke free"[TW] OR "smoke-free"[TW]) AND (model\*[TW] OR  
56 simulat\*[TW]) AND (cost[TW] OR economic[TW]).

57 We identified six economic evaluations of commercial tobacco endgame strategies,  
58 including different interventions and cost perspectives. Five studies modelled interventions  
59 in the Aotearoa/New Zealand (A/NZ) context and one in the UK. Four studies were  
60 conducted from a healthcare system perspective, estimating the costs to the health system  
61 associated with tobacco-related diseases. One of these studies additionally estimated 'non-  
62 health social costs', as the productivity loss resulting from smoking-associated morbidity  
63 and mortality. Another study estimated the cost to consumers resulting from a policy in  
64 which retail outlets selling tobacco were significantly reduced, considering both the actual  
65 cost of a pack of cigarettes and the cost of increased travel to retailers, and the last  
66 estimated excise tax revenue to the government resulting from increases to tobacco  
67 taxation (compared to no increases to current tobacco tax levels). Of the identified  
68 literature, none evaluated the effect of endgame strategies on citizen income nor the fiscal  
69 impacts to government revenue and expenditure.

70

### 71 **Added value of this study**

72 This study evaluates the economic impacts of a recently introduced commercial tobacco  
73 endgame legislation in A/NZ. We modelled the economic impacts by 2050 of a policy  
74 package that includes the four key measures in the new legislation (i.e., denicotinisation of  
75 smoked tobacco products, enhanced antismoking mass media campaigns, 90% reduction in  
76 the number of tobacco retail outlets, and a smoke-free generation law that bans sale of  
77 tobacco to anyone born after 2008). The analysis presents both a government and citizen

78 perspective. The government fiscal impacts extend beyond health system expenditure to  
79 also include differences between business as usual (BAU) – i.e., no endgame strategy – and  
80 endgame scenarios in excise tax revenue, goods and services tax (GST) revenue, income tax  
81 revenue, and superannuation expenditure. A net government position is also calculated. The  
82 citizen perspective estimates the impact of the policy on population income and savings that  
83 may result from reduced tobacco consumption. Our model projects large economic gains for  
84 consumers from the tobacco endgame package resulting from a sharp reduction in smoking  
85 prevalence, morbidity and mortality. For the A/NZ Government, the policy is projected to  
86 result in reduced healthcare costs, and increased income tax and GST revenue. These gains  
87 are offset by increased superannuation payments resulting from a greater number of  
88 individuals living past the age at which superannuation is provided to all citizens (65 years in  
89 A/NZ and described in this article as “retirement age” for simplicity), as well as large  
90 reductions in excise tax revenue.

91

## 92 **Implication of all the available evidence**

93 Our findings support previous evidence indicating that ambitious tobacco control policies  
94 can produce large health and economic benefits. Our model suggests that a commercial  
95 tobacco endgame strategy is likely to result in a large revenue transfer to the benefit of the  
96 A/NZ population. An endgame approach moves beyond the BAU model of incremental  
97 policy change to a deliberate strategy to permanently reduce tobacco smoking to minimal  
98 levels within a short timeframe. A logical result of such a strategy is a significant decrease in  
99 excise tax revenue for governments. Under the endgame scenario, the net position of the  
100 A/NZ Government is likely to be negative due mainly to the foregone excise tax revenue. In  
101 a sensitivity analysis of the endgame scenario that takes into account recent projections  
102 from Stats NZ of a future larger and older labour force in A/NZ, our model suggests that the  
103 net government position might become positive as early as 2036 – less than 15 years after  
104 the introduction of the endgame policy.

105

## 106 INTRODUCTION

107

108 Smoking is a leading cause of avoidable morbidity and mortality.<sup>1</sup> Globally, the annual  
109 economic loss due to smoking has been estimated at US\$1,436 billion, equivalent in  
110 magnitude to 1.8% of the world's annual gross domestic product (GDP).<sup>2</sup> In the United  
111 States (US) alone, the annual loss in income and unpaid household production due to  
112 tobacco consumption has been estimated at \$436 billion per annum - equivalent to 2.1 % of  
113 the 2020 GDP for that country.<sup>3</sup>

114

115 In this context of massive health and economic losses due to tobacco, commercial tobacco  
116 endgame strategies are being increasingly proposed and regarded as a viable approach to  
117 tackle the tobacco epidemic.<sup>4</sup> An endgame approach moves beyond the business-as-usual  
118 (BAU) model of incremental policy change to a deliberative strategy to permanently reduce  
119 tobacco smoking to minimal levels within a short timeframe, or a complete phase out of the  
120 commercial tobacco market. The endgame concept is often interpreted as a smoking  
121 prevalence of  $\leq 5\%$  in the adult population.<sup>5</sup> As of early 2023, ten countries (including  
122 Aotearoa-New Zealand [A/NZ], England, Scotland, Republic of Ireland, US, Canada, Australia,  
123 Sweden, Finland, and Bangladesh) have announced goals to reach the  $\leq 5\%$  target between  
124 2025 and 2040.<sup>6</sup>

125

126 Among these countries, A/NZ is the first to pass into law a package of policies aiming to  
127 reduce smoking prevalence to  $\leq 5\%$  prevalence before 2030 and to reduce the inequity in  
128 smoking rates between the Māori (Indigenous) and non-Māori populations. When  
129 operationalised, the Smokefree Environments and Regulated Products (Smoked Tobacco)  
130 Amendment Act, which was passed by the Parliament in December 2022,<sup>7</sup> will reduce the  
131 nicotine content of all smoked tobacco products to non-addictive levels, reduce the number  
132 of tobacco retail outlets by at least 90%, and ban tobacco sales to anyone born after 2008.<sup>8</sup>  
133 These new policies are likely to be accompanied by enhanced smoking cessation support,  
134 grants to engage community groups in activities to achieve the smokefree goal and other  
135 health promotion activities. In a recent study we evaluated the potential health impacts of  
136 these policies and found that their implementation would deliver large health and equity  
137 gains compared to a BAU approach.<sup>10</sup> According to our modelling, a combined tobacco

138 endgame policy package would lead to a gain of 594,000 health-adjusted life years (HALYs;  
139 95% uncertainty interval [UI]: 443,000 to 738,000; 3% discount rate) over the remaining  
140 lifetime of the 5.08 million A/NZ population alive in 2020.<sup>9</sup>

141

142 Despite the unprecedented potential for a commercial tobacco endgame to increase  
143 population health and equity, and to reduce healthcare expenditure and lost productivity  
144 due to premature death and disability, phasing out commercial tobacco sales often raises  
145 concerns about economic impacts on governments from loss of tobacco taxes. In this study,  
146 we aimed to quantify the potential economic effects of the Smokefree Aotearoa 2025  
147 Action Plan from both Government and citizen perspectives.

148

## 149 **METHODS**

150 We used a previously published simulation model<sup>9</sup> developed to evaluate the health  
151 impacts of the A/NZ Smokefree Action Plan. Details of the model's methodology, design,  
152 assumptions and epidemiological parameters have been reported elsewhere.<sup>9-12</sup> Briefly, the  
153 simulation is based on the combination of two models: 1) a Markov process simulating the  
154 population's smoking and vaping life history based on seven states (see supplementary  
155 Figure S1). Movements between the different states are determined by transition  
156 probabilities, which reflect BAU and additional super-imposed effects of the intervention  
157 (see below); 2) a proportional multistate lifetable (PMSLT) composed of a main cohort  
158 lifetable, which simulates the evolution of A/NZ population from 2020 using projected all-  
159 cause mortality and morbidity rates. For this analysis, we evolved the model from a closed-  
160 cohort to an open-cohort simulation by including births and migration using projections  
161 from Stats NZ (the A/NZ official data agency). In parallel, in the BAU scenario, proportions of  
162 the cohort also reside in 16 subsidiary tobacco-related disease lifetables according to  
163 prevalence at baseline, and in future years based on BAU disease-specific incidence, case  
164 fatality and remission rates (where appropriate e.g., for treated cancers). The tobacco-  
165 related diseases in the model are coronary heart disease, stroke, chronic obstructive  
166 pulmonary disease (COPD), lower respiratory tract infection (LRTI), and the following  
167 cancers: lung, oesophageal, stomach, liver, head and neck, pancreas, cervical, bladder,  
168 kidney, endometrial, melanoma, and thyroid.

169

170 **Economic outcomes**

171 Table 1 lists the economic input parameters included in the model and their sources. We  
172 identified baseline estimates of total population income, total government income tax  
173 revenue, goods and services tax (GST) revenue, tobacco excise tax revenue, superannuation  
174 expenditure and health expenditure for the year 2021 from the Financial statement of the  
175 Government of A/NZ.<sup>13</sup> Within each disease lifetable, these parameters were allocated by  
176 five-year age groups to proportions of the cohort as follows: population income was  
177 attached to cohorts aged 20 to 64 years, superannuation payments were attached to  
178 cohorts aged 65 years and older, tobacco excise was attached to the proportion smoking.  
179 Health expenditure by disease was attached to all cohorts. The model was calibrated to  
180 produce values that match the baseline economic parameter estimates after one cycle run  
181 (i.e., 2021). Table 2 presents the economic outcomes produced by the model and their  
182 calculation method.

183

184 For each simulated year, a population impact fraction (PIF) is calculated for each tobacco-  
185 related disease. The generic formula<sup>14</sup> is:

186

$$PIF_{idt} = \frac{\sum_{j=1}^n P_j RR_{idj} - \sum_{j=1}^n P'_j RR_{idj}}{\sum_{j=1}^n P_j RR_{idj}}$$

187 where:

188 i subscripts each sex by age by ethnic group

189 d subscripts each disease

190 t subscripts each time step or yearly cycle

191 j subscripts each category of smoking or vaping (the seven states in supplementary Figure 1,  
192 plus 20 additional tunnel states for each of those quitting smoking and/or vaping and people  
193 who switched completely from smoking to vaping)

194 RR is the incidence rate ratio for disease d and smoking-vaping state j, and possible varying  
195 by demographics (e.g., by sex and age, but not by ethnic group). (Note the RR does not vary  
196 by time step t.)

197



198 These PIFs are the percentage change (compared to BAU) in incidence rates for each  
199 smoking-related disease, by socio-demographics and year, that are transferred to the  
200 PMSLT.

201

202 Within each disease lifetable, the endgame intervention is run in parallel to BAU with  
203 different disease incidence rates given changes in smoking and vaping prevalence over time  
204 (see supplementary Figure S1). Each disease lifetable estimates the difference between  
205 intervention and BAU in disease mortality, morbidity, and the modelled economic outputs  
206 (Table 2). These differences are calculated at the end of each one-year cycle then added to  
207 matching entities in the all-cause or main lifetable.

208

### 209 **Intervention**

210 Intervention effects were reflected in the model through changes in population movements  
211 (i.e., transition probabilities) between smoking and vaping states. The endgame policy  
212 package considered in the model combines the effects of four separate interventions  
213 included in the Smokefree Aotearoa 2025 Action Plan: 1) denicotinisation, 2) enhanced mass  
214 media campaign, 3) 95% reduction in the number of tobacco retail outlets; and 4) smoke-  
215 free generation. Parameterisations of the individual policies and the combined smokefree  
216 policy package are described in Supplementary Table S1. This paper focuses on the  
217 combined effect of these interventions if implemented as a single policy package in 2023.

218

### 219 **Sensitivity analysis: dynamic retirement age scenario**

220 The economic outcomes based on transfer payments between Government and citizens  
221 included in our model are heavily dependent on the evolution of the labour force in A/NZ.  
222 Therefore, our projection of the net government position (i.e., once all the transfers have  
223 been considered) is likely to be sensitive to the size and participation of the working-age  
224 population. The latest report from Stats NZ National Labour force projections estimates that  
225 by 2043 the median size of the labour force in A/NZ will rise by 17.2% compared to 2020.  
226 Over the same period, the proportion of the labour force aged 65 years and older is  
227 projected to increase from 6% in 2020 to 7-11% in 2043 and 7-15% in 2073.<sup>15</sup>

228

229 To test the sensitivity of our model to these labour force evolutions, we developed an  
230 alternative endgame scenario with a ‘dynamic’ age of retirement and access to  
231 superannuation (i.e., pension payments). Under this scenario, the threshold age increases  
232 each year so that the citizen morbidity rate (people who do and do not smoke combined)  
233 under the intervention matches the morbidity rate of a 65-year-old under BAU (i.e., without  
234 the tobacco endgame intervention). That is, the dynamic scenario is one way to try and  
235 capture the contribution that a prevention program such as the A/NZ tobacco endgame  
236 legislation might make to the healthiness and thence productivity of the population.

237

238 This firstly involved measuring prevalent Years Lived with Disability (pYLDs; measure of  
239 average morbidity for a given population) for age 65–70-year-olds, for each year up to 2050,  
240 as follows:

241

$$pYLD = 1 - (\text{Health Adjusted Life Years (HALYs)} / \text{Person Years (PYs)})$$

242

243 Secondly, for each year, the updated age of superannuation entitlements (i.e., the dynamic  
244 retirement age) was calculated as follows:

245

*Dynamic yearly retirement age*

$$= 65 + \left( \frac{BAU\ pYLDs_{65\ yrs} - Endgame\ pYLDs_{65\ yrs}}{Endgame\ pYLDs_{66\ yrs} - Endgame\ pYLDs_{65\ yrs}} \right)$$

246

247 HALYs and Person-Years (PYs) for the above equation were calculated within the PMSLT for  
248 both BAU and the alternative endgame scenario.<sup>16</sup>

249

250 All scenarios were run 2000 times in Monte Carlo simulation. A 3% discount rate per annum  
251 was applied to all economic measures. Undiscounted results are provided in the online  
252 supplementary material. Estimates were calculated in 2021 NZ\$ then converted to US\$  
253 using a 2021 NZ-US OECD purchasing power parity adjustment of 1.4684.

254

255 **RESULTS**

256 Figure 1 shows the annual differences in costs between the endgame scenario and BAU.

257 Table 3 presents the cumulative expenditure and revenue estimates.

258

259 For the endgame scenario compared to BAU, health system expenditure savings discounted  
260 at 3% per annum are projected to peak in 2044 at US\$65m (95% UI: 49 to 83) before  
261 decreasing to US\$53m (95% UI: 35 to 72) in 2050. The health system is projected to save a  
262 cumulative total of US\$1.34 billion (b) (95% UI: 1.02 to 1.7) by 2050. Conversely,  
263 government expenditure in superannuation benefits will increase by a cumulative total of  
264 US\$1.18b (95% UI: 0.93 to 1.44), over the same period, due to people living longer.

265

266 Population income (after tax) increases on average by US\$5m every year after the  
267 introduction of the policy (i.e., 2023), reaching US\$138m annually (95% UI: 113 to 166) in  
268 2050. This represents a projected cumulative income gain of US\$1.8b (95% UI: 1.4 to 2.1) by  
269 2050. This increase in income leads to a parallel increase in government income tax  
270 revenue.

271

272 If money not spent on cigarettes is diverted to other expenditure in the economy, then the  
273 effective increase in cumulative disposable income is projected to be US\$31.16b (95% UI:  
274 24.3 to 37.4) by 2050. Assuming the increase in disposable income is fully spent in the  
275 economy, government GST revenue increases by a cumulative total of US\$1.24b (0.99 to  
276 1.48) by 2050.

277

278 Annual Government revenue from tobacco excise for the endgame scenario compared to  
279 BAU falls rapidly to a maximum of US\$735m (608 to 837) less revenue in 2027. The  
280 cumulative excise tax revenue foregone by 2050 is US\$13.5b (95% UI: 10.5 to 16.4).

281

282 The net of revenue and expenditure differences between the endgame and BAU from the  
283 Government perspective is dominated by the tobacco excise tax loss. There is a net loss for  
284 the Government in every year out to 2050, and a cumulative negative net position of  
285 US\$11.51b (95% UI: 8.7 to 14.0) by 2050.

286

287 Figure 2 and Table 4 show the same results, but for the scenario analysis that sees the age  
288 of retirement and eligibility for superannuation increase over time, so the new threshold  
289 age has the same morbidity as 65-year-olds in BAU. Under this scenario, the age threshold  
290 for entitlement to superannuation becomes 65.2 years in 2030, 65.5 years in 2040 and 65.8  
291 years in 2050. The Government's net annual position compared to BAU becomes positive  
292 by 2037 (Figure 2) – due to changes in income tax revenue and superannuation payments.  
293 This scenario still resulted in a net cumulative loss to the Government of US\$1.89b (-4.74 to  
294 1.01) by 2050 but is only 14% of the similar loss with a static age.

295

## 296 **DISCUSSION**

297 Our modelling suggests that the Smokefree Aotearoa 2025 Action Plan recently passed into  
298 law by the A/NZ Government is likely to produce substantial economic benefits in addition  
299 to the previously calculated<sup>9</sup> health and health equity benefits. Under this scenario, the  
300 population would benefit from a cumulative gain in post-tax income of US\$1.8 billion by  
301 2050. Factoring in consumer savings on tobacco expenditure, leads to a cumulative increase  
302 of US\$31 billion in total disposable income by 2050. Our estimates are consistent with a  
303 large body of evidence documenting the detrimental impact of tobacco spending on  
304 household budgets, particularly for the most disadvantaged socio-economic categories.<sup>17</sup> An  
305 analysis of A/NZ census data has estimated that among low-income households with at least  
306 one member who smokes, up to 14% of the non-housing budget was spent on tobacco.<sup>18</sup>  
307 Similar findings have been reported in other high-income countries<sup>19</sup> as well as low-<sup>20,21</sup> and  
308 middle-income countries.<sup>22,23</sup> A recent modelling study evaluating the economic loss  
309 attributable to cigarette smoking in the US estimated the total loss in annual population  
310 income in 2020 at US\$735.1 billion.<sup>3</sup> In A/NZ Moreover, smoking is strongly concentrated  
311 among Indigenous Māori and people on low incomes<sup>24</sup>, therefore our estimated increases  
312 in disposable income would represent a pro-equity income transfer.

313

314 From a government perspective, the picture is more mixed. A/NZ has one of the world's  
315 highest tobacco excise tax. In 2021, the pack price of 20 Marlboro cigarettes was NZ\$36.9  
316 (US\$25) with excise tax and GST representing 70% of the price. Consequently, the  
317 Government foregoes considerable excise tax revenue under the endgame policy scenario.  
318 Despite clear direct financial benefits (from reduced health expenditure and increases to

319 both GST from higher population income and income tax revenue), the Government's long-  
320 term net position remains negative in our primary analysis with a fixed age eligibility to  
321 superannuation benefit, due to the decline of excise tax revenue (Figure 1). This decrease in  
322 revenue is a logical consequence of successfully reducing smoking prevalence and was  
323 identified in the Regulatory Impact Statement preceding the legislation.<sup>8</sup>

324

325 Tobacco excise tax revenue also decreased under BAU – this is again a logical result of the  
326 underlying decreasing trend in smoking prevalence.<sup>24</sup> The endgame policy simply  
327 accelerates the rate of decline of this revenue source. In 2019/20, tobacco tax revenue was  
328 about 1.7% of annual A/NZ Government revenue,<sup>13</sup> which is relatively small compared to  
329 annual variation in government revenue arising from typical macroeconomic fluctuations  
330 and natural hazards that have impacted A/NZ in recent decades (major earthquakes, major  
331 storms and the Covid-19 pandemic).

332

333 Previous analyses that examined the impact of reducing smoking in the US to 10.4% (the  
334 estimated impact of the Institute of Medicine (IOM) recommended policy package) or to  
335 5.7% (a hypothetical high impact scenario) by 2025 on a range of economic outcomes also  
336 found the high impact scenario would reduce state government tobacco tax revenue on  
337 average by 2.5% due to the greater decline in cigarette sales, while the IOM policy package  
338 would produce a 0.5% increase by raising the tax rate.<sup>25</sup>

339

340 Through its world first tobacco endgame legislation, the A/NZ Government has prioritised  
341 health and equity over government revenue with three of the five political parties in the  
342 Parliament also fully supporting it (and the main opposition party still supportive of the  
343 denicotinisation policy). However, in countries where economic priorities are perceived as  
344 more important,<sup>5</sup> the cost to government revenue may present a major potential barrier to  
345 progressing a tobacco endgame. This may be particularly challenging in low- and middle-  
346 income countries, which may not yet be experiencing the full adverse health and economic  
347 impacts of the tobacco epidemic while collecting tobacco tax revenue from growing tobacco  
348 sales. Our modelling, although specific to the A/NZ context, assumes that a tobacco  
349 endgame strategy is likely to result in large economic benefits for the population and that  
350 revenue foregone by governments is not lost but rather re-transferred to the population. A

351 tobacco endgame may also address a key ethical challenge that tobacco taxation can pose in  
352 terms of contributing to financial hardship among low-income households where smoking  
353 persists.

354

355 Our study estimated an increase in government spending on aged pensions over time due to  
356 the reduction in premature mortality from tobacco-related disease – assuming a fixed age of  
357 eligibility to universal Government superannuation. Tobacco companies have previously  
358 attempted to sell the ‘financial benefits’ of smoking to governments in the form of reduced  
359 expenditure on aged pensions due to the reduced life expectancy.<sup>26</sup> However, since  
360 increasing life expectancy and health is a societal (and government) goal, increased financial  
361 costs associated with such health benefits in the form of government superannuation/aged  
362 pensions should not be a determining factor in government-decision making regarding  
363 policies that have life extending benefits.<sup>27</sup> Nevertheless, estimating these impacts can  
364 assist the A/NZ government to plan appropriately as the country becomes smokefree.

365

366 Acknowledging current Stats NZ projections of a larger and older working-age population in  
367 A/NZ, our sensitivity analysis scenario using a dynamic “retirement age” suggests that the  
368 government can achieve a positive net fiscal position despite the losses in excise tax  
369 revenue associated with the endgame policy package. This ‘recovery’ occurs only 14-years  
370 after the introduction of the policy and with minor incremental increases to the age of  
371 superannuation entitlement – from 65 years in 2020 to 65.78 years by 2050. Such a policy is  
372 consistent with changes being implemented in other similar countries. For example,  
373 Australia is currently gradually increasing the eligibility age for the aged pension from 65  
374 years at 30 June 2017 to 67 years on 1 July 2023.<sup>28</sup> Nevertheless, our dynamic scenario is  
375 just that – a scenario. No Government would change the retirement age and age of  
376 eligibility for universal superannuation benefits by such small increments per annum. Our  
377 purpose was to demonstrate how increased healthiness of the population might manifest as  
378 one way for society to adjust.

379

380 This study used a tobacco policy model ranked top of 15 such models internationally.<sup>29</sup>  
381 However, it has several limitations. Our modelling attempts to estimate what the future  
382 might look like and so has many uncertainties. To help capture these uncertainties we

383 applied a probabilistic sensitivity analysis approach to the key parameters in our simulation  
384 (in line with the recommendations for best practice<sup>30</sup>) to generate uncertainty ranges for  
385 the outputs. The model also relies on multiple assumptions and is therefore exposed to the  
386 limitations associated with those assumptions (see full discussion of model limitations in the  
387 main manuscript and supplementary material of Ait Ouakrim et al<sup>9</sup>). In our model, ‘retail  
388 reduction’ was specified as a 95% reduction in the number of tobacco retailers, based on  
389 earlier pre-legislation plans. However, the final version of the ‘smokefree bill’ adopted a  
390 minimum 90% reduction in tobacco retail stores which translates to a maximum of 600  
391 retail outlets. This might slightly over-estimate the projected economic benefits and,  
392 conversely, under-estimate the expenditure associated with the endgame policy package.

393

394 Our estimate of the net government position should be interpreted with caution as it is only  
395 limited to the macroeconomic outputs considered in the model. For example, the model did  
396 not take into account the health benefits (and subsequent economic dividends) that the  
397 endgame might produce as a result of lower population exposure to second hand  
398 smoke.<sup>31,32</sup> Similarly, we did not take into account the many Government tax revenue  
399 sources (such as corporate tax, taxes on payroll and workforce, tax on production etc.) that  
400 are likely to increase and benefit from a healthier and more productive population. Finally,  
401 our model did not account for the out-of-pocket health expenditure savings for citizens that  
402 would result from lower disease and treatment burden associated with quitting and lower  
403 uptake of smoking.

404

405 Smoking imposes intangible detrimental effects on people and society (for example the  
406 psychological pain associated with chronic addiction, tobacco-related disease and the  
407 prospect of premature death). These effects impact quality of life and productivity in the  
408 formal and informal economies. But they are hard to value quantitatively and our model  
409 does not take them into account. Consequently, our estimates of both the economic  
410 benefits of the tobacco endgame are likely to be under-estimates.

411

## 412 **CONCLUSION**

413 Our study estimated the expected economic impacts of the Smokefree Aotearoa 2025  
414 Action Plan, demonstrating economic benefits for the A/NZ population, and modest impacts

415 on government revenue and expenditure related to the reduction in tobacco tax and  
416 increases in aged pensions due to increased life expectancy. Such costs are relatively small  
417 compared to other macroeconomic fluctuations, and can be anticipated and planned for.  
418 These costs could be offset by future increases in labour force and the proportion of 65+  
419 year olds working in the formal economy.



## 420 **References**

- 421 1. Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S, Murray CJ. Selected major risk  
422 factors and global and regional burden of disease. *the lancet* 2002; **360**(9343): 1347-60.
- 423 2. Goodchild M, Nargis N, d'Espaignet ET. Global economic cost of smoking-attributable  
424 diseases. *Tobacco control* 2018; **27**(1): 58-64.
- 425 3. Nargis N, Hussain AG, Asare S, et al. Economic loss attributable to cigarette smoking  
426 in the USA: an economic modelling study. *The Lancet Public Health* 2022; **7**(10): e834-e43.
- 427 4. Malone RE. The race to a tobacco endgame. BMJ Publishing Group Ltd; 2016. p. 607-  
428 8.
- 429 5. Moon G, Barnett R, Pearce J, Thompson L, Twigg L. The tobacco endgame: the  
430 neglected role of place and environment. *Health & place* 2018; **53**: 271-8.
- 431 6. Puljević C, Morphet K, Hefler M, et al. Closing the gaps in tobacco endgame  
432 evidence: a scoping review. *Tobacco Control* 2022; **31**(2): 365-75.
- 433 7. Parliament NZ. Smokefree Environments and Regulated Products (Smoked Tobacco)  
434 Amendment Act 2022 (2022/79). 2022. [https://www.parliament.nz/en/pb/bills-and-](https://www.parliament.nz/en/pb/bills-and-laws/bills-proposed-laws/document/BILL_125245/smokefree-environments-and-regulated-products-smoked-tobacco)  
435 [laws/bills-proposed-laws/document/BILL\\_125245/smokefree-environments-and-regulated-](https://www.parliament.nz/en/pb/bills-and-laws/bills-proposed-laws/document/BILL_125245/smokefree-environments-and-regulated-products-smoked-tobacco)  
436 [products-smoked-tobacco](https://www.parliament.nz/en/pb/bills-and-laws/bills-proposed-laws/document/BILL_125245/smokefree-environments-and-regulated-products-smoked-tobacco).
- 437 8. Ministry of Health. Regulatory Impact Statement: Smokefree Aotearoa 2025 Action  
438 Plan. Wellington: Ministry of Health 2021. 2021. [https://www.health.govt.nz/about-](https://www.health.govt.nz/about-ministry/information-releases/regulatory-impact-statements/regulatory-impact-statement-smokefree-aotearoa-2025-action-plan)  
439 [ministry/information-releases/regulatory-impact-statements/regulatory-impact-statement-](https://www.health.govt.nz/about-ministry/information-releases/regulatory-impact-statements/regulatory-impact-statement-smokefree-aotearoa-2025-action-plan)  
440 [smokefree-aotearoa-2025-action-plan](https://www.health.govt.nz/about-ministry/information-releases/regulatory-impact-statements/regulatory-impact-statement-smokefree-aotearoa-2025-action-plan) (accessed 5/02/2023).
- 441 9. Ait Ouakrim D, Wilson T, Waa A, et al. Tobacco endgame intervention impacts on  
442 health gains and Māori:non-Māori health inequity: a simulation study of the Aotearoa/New  
443 Zealand Tobacco Action Plan. *Tobacco Control* 2023: tc-2022-057655.
- 444 10. Blakely T, Cobiac LJ, Cleghorn CL, et al. Health, health inequality, and cost impacts of  
445 annual increases in tobacco tax: multistate life table modeling in New Zealand. *PLoS*  
446 *medicine* 2015; **12**(7): e1001856.

- 447 11. Pearson AL, Cleghorn CL, van der Deen FS, et al. Tobacco retail outlet restrictions:  
448 health and cost impacts from multistate life-table modelling in a national population. *Tob*  
449 *Control* 2016.
- 450 12. Petrović-van der Deen FS, Blakely T, Kvizhinadze G, Cleghorn CL, Cobiac LJ, Wilson N.  
451 Restricting tobacco sales to only pharmacies combined with cessation advice: a modelling  
452 study of the future smoking prevalence, health and cost impacts. *Tobacco control* 2019;  
453 **28**(6): 643-50.
- 454 13. Treasury NZ. Financial statement of the Government of New Zealand (year ending  
455 June 2021). Available from: . 2021.
- 456 14. Murray CJ, Ezzati M, Lopez AD, Rodgers A, Vander Hoorn S. Comparative  
457 quantification of health risks: conceptual framework and methodological issues. *Population*  
458 *health metrics* 2003; **1**(1): 1-20.
- 459 15. Stats New Zealand. National labour force projections: 2020(base)–2073. 2021.  
460 [https://www.stats.govt.nz/information-releases/national-labour-force-projections-](https://www.stats.govt.nz/information-releases/national-labour-force-projections-2020base-2073)  
461 [2020base-2073](https://www.stats.govt.nz/information-releases/national-labour-force-projections-2020base-2073) (accessed 9/02/2023).
- 462 16. Blakely T, Moss R, Collins J, et al. Proportional multistate lifetable modelling of  
463 preventive interventions: concepts, code and worked examples. *International Journal of*  
464 *Epidemiology* 2020; **49**(5): 1624-36.
- 465 17. National Cancer Institute, World Health Organization. The Economics of Tobacco and  
466 Tobacco Control. National Cancer Institute Tobacco Control Monograph 21. NIH Publication  
467 No. 16-CA-8029A. Bethesda, MD: U.S. Department of Health and Human Services, National  
468 Institutes of Health, National Cancer Institute; and Geneva, CH: World Health Organization.  
469 2016. [https://cancercontrol.cancer.gov/brp/tcrb/monographs/21/docs/m21\\_complete.pdf](https://cancercontrol.cancer.gov/brp/tcrb/monographs/21/docs/m21_complete.pdf).
- 470 18. Thomson GW, Wilson N, O’dea D, Reid P, Howden-Chapman P. Tobacco spending  
471 and children in low income households. *Tobacco Control* 2002; **11**(4): 372-5.
- 472 19. Nyakutsikwa B, Britton J, Langley T. The effect of tobacco and alcohol consumption  
473 on poverty in the United Kingdom. *Addiction* 2021; **116**(1): 150-8.

- 474 20. Husain MJ, Datta BK, Virk-Baker MK, Parascandola M, Khondker BH. The crowding-  
475 out effect of tobacco expenditure on household spending patterns in Bangladesh. *PloS one*  
476 2018; **13**(10): e0205120.
- 477 21. Nguyen N-M, Nguyen A. Crowding-out effect of tobacco expenditure in Vietnam.  
478 *Tobacco Control* 2020; **29**(Suppl 5): s326-s30.
- 479 22. San S, Chaloupka FJ. The impact of tobacco expenditures on spending within Turkish  
480 households. *Tobacco control* 2016; **25**(5): 558-63.
- 481 23. Wang H, Sindelar JL, Busch SH. The impact of tobacco expenditure on household  
482 consumption patterns in rural China. *Social science & medicine* 2006; **62**(6): 1414-26.
- 483 24. Ministry of Health. Annual Data Explorer 2021/22: New Zealand Health Survey  
484 Tobacco Use. 2022. [https://minhealthnz.shinyapps.io/nz-health-survey-2021-22-annual-](https://minhealthnz.shinyapps.io/nz-health-survey-2021-22-annual-data-explorer/)  
485 [data-explorer/](https://minhealthnz.shinyapps.io/nz-health-survey-2021-22-annual-data-explorer/).
- 486 25. Bearman PS, Neckerman KM, Wright L. After tobacco: what would happen if  
487 Americans stopped smoking?: Columbia University Press; 2011.
- 488 26. Ross H. Critique of the Philip Morris study of the cost of smoking in the Czech  
489 Republic. *Nicotine & tobacco research* 2004; **6**(1): 181-9.
- 490 27. Barendregt JJ, Bonneux L, van der Maas PJ. The health care costs of smoking. *New*  
491 *England Journal of Medicine* 1997; **337**(15): 1052-7.
- 492 28. Services AGDoS. Seniors Benefits & Payments - Age Pension. 2023.  
493 <https://www.dss.gov.au/seniors/benefits-payments/age-pension> (accessed 15 February  
494 2023).
- 495 29. Huang V, Head A, Hyseni L, et al. Identifying best modelling practices for tobacco  
496 control policy simulations: a systematic review and a novel quality assessment framework.  
497 *Tobacco control* 2022.
- 498 30. Briggs AH, Weinstein MC, Fenwick EA, Karnon J, Sculpher MJ, Paltiel AD. Model  
499 parameter estimation and uncertainty analysis: a report of the ISPOR-SMDM Modeling  
500 Good Research Practices Task Force Working Group–6. *Medical decision making* 2012; **32**(5):  
501 722-32.

- 502 31. Callinan JE, Clarke A, Doherty K, Kelleher C. Legislative smoking bans for reducing  
503 secondhand smoke exposure, smoking prevalence and tobacco consumption. *Cochrane*  
504 *Database Syst Rev* 2010; (4).
- 505 32. Christensen TM, Møller L, Jørgensen T, Pisinger C. The impact of the Danish smoking  
506 ban on hospital admissions for acute myocardial infarction. *European journal of preventive*  
507 *cardiology* 2014; **21**(1): 65-73.
- 508 33. Stats New Zealand. Earnings for people in paid employment by region, sex, age  
509 groups and ethnic groups.  
510 [https://nzdotstat.stats.govt.nz/wbos/index.aspx?\\_ga=2.59390884.807928993.1671346727-](https://nzdotstat.stats.govt.nz/wbos/index.aspx?_ga=2.59390884.807928993.1671346727-697363774.1671144874#)  
511 [697363774.1671144874#](https://nzdotstat.stats.govt.nz/wbos/index.aspx?_ga=2.59390884.807928993.1671346727-697363774.1671144874#)
- 512 34. Blakely T, Sigglekow F, Irfan M, et al. Disease-related income and economic  
513 productivity loss in New Zealand: A longitudinal analysis of linked individual-level data. *PLoS*  
514 *medicine* 2021; **18**(11): e1003848.
- 515 35. Drope J, Hamill S, Chaloupka F, et al. The Tobacco Atlas. 2022.  
516 <https://tobaccoatlas.org/>.

**Table 1. Base-year (2021) annual cost inputs to the modelling, and application within model**

Parameter	Value	Source	Model application
Total population income	\$124.5 billion	33	Disaggregated to expected income per citizen, by sex and age (20-64-year-olds only*). <u>Gamma distribution, SD = +/- 10% of mean</u>
Income loss due to tobacco-related diseases	N/A	34	Each tobacco-related disease had an income loss attached (by sex and age). <u>Independent gamma distributions, SD = +/- 10% of expected income loss from disease.</u> Not used in BAU. Under the intervention scenario, the difference in income loss (usually a gain in income as less disease) between intervention and BAU was added to the expected average citizen income above.
Total health system expenditure	\$15.52 billion	13	Disaggregated to expected health system expenditure per person, by sex and age. <u>Gamma distribution, SD = +/- 10% of mean</u>
Health system expenditure for tobacco-related diseases	N/A	34	Each tobacco-related disease (by sex and age by phase (first year of diagnosis, last year of life if dying of disease, otherwise prevalent with disease)) had an expenditure attached. <u>Independent gamma distributions, SD = +/- 10%.</u> Not used in BAU. Under the intervention scenario, the difference in disease expenditure (usually a reduction as less disease) between intervention and BAU was added to the expected average health system expenditure above.
Income tax revenue	\$32.93 billion	13	Divided by population income to give <b>income tax rate</b> (32.93/124.5 = 26.45% of total population income.)
GST revenue	\$17.41 billion	13	Divided by population income to give <b>GST rate</b> (17.41/124.5 = 13.98% of total population income.)

Tobacco excise revenue	\$1.11 billion	13	Divided by size of the smoking population in 2021 to give tobacco <b>excise tax rate</b> (\$1922.7 per annum per person who smokes).
Proportion of the price (before GST) per pack of 25 cigarettes in A/NZ collected by government as excise tax <sup>#</sup>	55%	35	Tobacco excise revenue (above) divided by this value to give estimated total tobacco expenditure, then divided by size of the smoking population in 2021 to give population <b>tobacco expenditure rate</b> (\$3495.8 per annum per person who smokes).
Superannuation expenditure revenue	\$11.28 billion	13	Divided by number of 65+ year olds in 2021 to give <b>superannuation expenditure rate</b> (\$14,817 per annum per person age 65+ years).

Footnote: All costs presented are annual amounts, in 2021 US\$ (calculated using NZ-US OECD PPP of 1.4684).

<sup>#</sup> Ratio of tobacco industry revenue to excise tax revenue is 45%/55%<sup>35</sup>

**Table 2. Aggregate differences in economic outputs between tobacco endgame and BAU**

Output	Calculation
$\Delta$ Population income	Population income <sub>Intervention</sub> – Population income <sub>BAU</sub>
$\Delta$ After tax population income	$(\Delta \text{ Population income}) \times (1 - \text{income tax rate}^\ddagger)$
$\Delta$ GST revenue	$(\Delta \text{ Population income}) \times \text{GST rate}^\ddagger$
$\Delta$ Income tax revenue	Income tax rate <sup>‡</sup> $\times$ $\Delta$ population income
$\Delta$ Tobacco excise revenue	$(\text{Number of people who smoke}_{\text{Intervention}} - \text{Number of people who smoke}_{\text{BAU}}) \times \text{Tobacco excise tax rate}^\ddagger$
$\Delta$ Health system expenditure	Total health expenditure <sub>Intervention</sub> – Total health expenditure <sub>BAU</sub>
$\Delta$ GST revenue from tobacco sales	$0.15/1.15 \times (\text{Number of people who smoke}_{\text{Intervention}} - \text{Number of people who smoke}_{\text{BAU}}) \times \text{Tobacco expenditure rate}^\ddagger$
$\Delta$ Population expenditure on tobacco	$(\text{Number of people who smoke}_{\text{Intervention}} - \text{Number of people who smoke}_{\text{BAU}}) \times \text{Tobacco expenditure rate}^\ddagger$
$\Delta$ Superannuation expenditure	$(\text{Difference in population aged } 65^{+\#} \text{ between endgame and BAU}) \times \text{superannuation expenditure rate}^\ddagger$
$\Delta$ Government net position	$\Delta \text{ Income tax revenue} + \Delta \text{ Tobacco excise revenue} + \Delta \text{ GST revenue} - \Delta \text{ Health system expenditure} - \Delta \text{ Superannuation expenditure}$

\* Tobacco industry is defined as all producers and retailers – consistent with the calculation method.

<sup>#</sup> Age of superannuation entitlement varies under sensitivity analysis scenario with dynamic retirement age.

<sup>‡</sup> Parameter from Table 1

**Table 3: Projected changes in cumulative expenditure and revenue due to the Aotearoa-New Zealand's tobacco endgame strategy compared to BAU (2021 PPP US\$ billions; 3% annual discount rate)**

Revenue/expenditure items	by 2030		by 2040†		by 2050†	
	Estimate	95% UI	Estimate	95%	Estimate	95%
<b>Government perspective</b>						
<i>Expenditure</i>						
Health system	-0.18	(-0.22 to -0.14)	-0.73	(-0.90 to -0.57)	-1.34	(-1.70 to -1.02)
Superannuation expenditure	0.03	(0.02 to 0.04)	0.35	(0.28 to 0.43)	1.18	(0.93 to 1.44)
<i>Revenue</i>						
Income tax revenue	0.05	(0.04 to 0.06)	0.30	(0.24 to 0.35)	0.65	(0.52 to 0.77)
GST revenue (including tobacco sales tax)	0.37	(0.3 to 0.44)	0.84	(0.68 to 0.99)	1.24	(0.99 to 1.48)
Tobacco excise revenue	-5.24	(-6.16 to -4.24)	-10.35	(-12.26 to -8.24)	-13.56	(-16.39 to -10.53)
<b>Net Government position</b> <i>(<math>\sum</math>revenue – <math>\sum</math>expenditure)</i>	-4.67	(-5.49 to -3.77)	-8.83	(-10.52 to -6.96)	-11.51	(-14.03 to -8.77)
<b>Citizen perspective</b>						
Population income after tax	0.14	(0.11 to 0.17)	0.82	(0.66 to 0.98)	1.80	(1.46 to 2.15)
Savings from cessation (reduced tobacco expenditure)	11.35	(13.35 to 9.19)	22.41	(26.55 to 17.83)	29.36	(35.49 to 22.80)
Population income after tax + savings from cessation	11.49	(9.30 to 13.50)	23.20	(18.50 to 27.45)	31.16	(24.35 to 37.47)

Note: 2020 NZ\$ converted to 2021 US\$ using NZ-US OECD purchasing power parity of 1.4684.

† i.e., includes estimate to left, as cumulative over time.


**Table 4: Projected changes in cumulative expenditure and revenue due to the Aotearoa-New Zealand tobacco endgame strategy compared to BAU using dynamic retirement age (2021 PPP USD billions; 3% annual discount rate)**

Revenue/expenditure items	by 2030		by 2040†		by 2050†	
	Estimate	95% UI	Estimate	95%	Estimate	95%
<b>Government perspective</b>						
<i>Expenditure</i>						
Health system	-0.18	(-0.22 to -0.14)	-0.73	(-0.90 to -0.57)	-1.34	(-1.70 to -1.02)
Superannuation expenditure	-0.30	(-0.31 to -0.29)	-1.65	(-1.73 to -1.58)	-3.31	(-3.56 to -3.06)
<i>Revenue</i>						
Income tax revenue	0.29	(0.25 to 0.35)	1.78	(1.49 to 2.11)	3.98	(3.32 to 4.73)
GST revenue (including tobacco sales tax)	0.50	(0.43 to 0.58)	1.63	(1.4 to 1.88)	3.01	(2.57 to 3.49)
Tobacco excise revenue	-5.24	(-6.16 to -4.24)	-10.35	(-12.26 to -8.24)	-13.56	(-16.39 to -10.53)
<b>Net Government position</b> <i>(<math>\sum</math>revenue – <math>\sum</math>expenditure)</i>	-3.96	(-4.8 to -3.07)	-4.54	(-6.35 to -2.65)	-1.89	(-4.74 to 1.01)
<b>Citizen perspective</b>						
Population income after tax	0.82	(0.68 to 0.97)	4.96	(4.15 to 5.88)	11.07	(9.24 to 13.15)
Savings from cessation (reduced tobacco expenditure)	11.35	(13.35 to 9.19)	22.41	(26.55 to 17.83)	29.36	(35.49 to 22.8)
Population income after tax + savings from cessation	12.17	(9.95 to 14.2)	27.38	(22.52 to 31.78)	40.45	(33.18 to 47.3)

Note: 2020 NZ\$ converted to 2021 US\$ using NZ-US OECD purchasing power parity of 1.4684.

† i.e., includes estimate to left, as cumulative over time.

**Figure 1: Estimated annual differences in revenue and expenditure (2021 US\$; 3% annual discount rate) between the tobacco endgame scenario and BAU**





**Figure 2: Estimated annual differences in revenue and expenditure (2021 PPP US\$; 3% annual discount rate) between tobacco endgame scenario with dynamic retirement age and BAU (Government perspective)**

